Kolexia
Touzeau Cyrille Hématologie
Touzeau Cyrille
Hématologie
Hôpital Hôtel-Dieu Nantes
Nantes, France
422 Activités
49 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Myélome multiple Tumeurs à plasmocytes Lymphomes Récidive tumorale locale Lymphome à cellules du manteau Maladie résiduelle Leucémies Lymphome B Leucémie aigüe myéloïde

Collaborateurs

Voir plus
Moreau Philippe
Moreau Philippe
Hôpital Hôtel-Dieu Nantes, Nantes, France
Leleu Xavier
Leleu Xavier
Hôpital La Miletrie, Poitiers, France
Le Gouill Steven
Le Gouill Steven
Clcc Institut Curie, Paris, France
Perrot Aurore
Perrot Aurore
Oncopole Toulouse, Toulouse, France

Industries

Voir plus
Janssen
54 collaboration(s)
Dernière en 2023
Edimark
14 collaboration(s)
Dernière en 2023
Sanofi
14 collaboration(s)
Dernière en 2023
Celgene
13 collaboration(s)
Dernière en 2023

Dernières activités

Voir plus
A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma: A Phase 3, Two-stage, Randomized, Multi-center, Controlled, Open-label Study Comparing Iberdomide Maintenance to Lenalidomide Maintenance Therapy After Autologous Stem Cell Transplantation (ASCT) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) (EXCALIBER-Maintenance)
Essai Clinique (BMS)   20 mars 2024
KarMMa-9: A Randomized, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Idecabtagene Vicleucel With Lenalidomide Maintenance Versus Lenalidomide Maintenance Therapy Alone in Adult Participants With Newly Diagnosed Multiple Myeloma Who Have Suboptimal Response After Autologous Stem Cell Transplantation (KarMMa-9)
Essai Clinique (BMS)   18 mars 2024
RHUMM: Diagnostic Performance of Spot Urine Sample for the Monoclonal Components Detection in Patients With Multiple Myeloma RHU(M)M Random or H24 Urine in (Multiple) Myeloma
Essai Clinique (Intergroupe Francophone du Myélome)   15 mars 2024
A Study of JNJ-54767414 (HuMax CD38) (Anti-CD38 Monoclonal Antibody) in Combination With Backbone Treatments for the Treatment of Patients With Multiple Myeloma: An Open-Label, Multicenter, Phase 1b Study of JNJ-54767414 (HuMax CD38) (Anti-CD38 Monoclonal Antibody) in Combination With Backbone Regimens for the Treatment of Subjects With Multiple Myeloma
Essai Clinique (Janssen)   11 mars 2024
SUCCESSOR-1: A Phase 3, Two-Stage, Randomized, Multicenter, Open-Label Study Comparing Mezigdomide (CC-92480), Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Subjects With Relapsed or Refractory Multiple Myeloma (RRMM): SUCCESSOR-1
Essai Clinique (Celgene)   07 mars 2024
IsAMYP: A Phase 2, Open Label, Multicenter, Single-stage Study to Evaluate the Efficacy of Isatuximab Plus Pomalidomide and Dexamethasone (IPd), in Patients With AL Amyloidosis Not in VGPR or Better After Any Previous Therapy
Essai Clinique (BMS)   05 mars 2024
MagnetisMM-3: Study Of Elranatamab (PF-06863135) Monotherapy in Participants With Multiple Myeloma Who Are Refractory to at Least One PI, One IMiD and One Anti-CD38 mAb
Essai Clinique (Pfizer)   01 mars 2024
Résultats préliminaires de l’étude MyelofludaTEP évaluant la TEP à la [18F]Fludarabine pour le bilan initial et l’évaluation thérapeutique du myélome multiple
10e Journées Francophones de Médecine nucléaire - Biarritz   01 mars 2024
Characteristics and incidence of infections in patients with multiple myeloma treated by bispecific antibodies: a national retrospective study on the behalf of G2I and IFM.
Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases   01 mars 2024
Le point sur la prise en charge du myélome multiple
Edimark   28 février 2024